ebola
mainli
zair
strain
relat
ebola
viru
declar
wide
spread
deadli
persist
epidem
due
unavail
rapid
diagnost
detect
therapeut
ebola
viru
diseas
evd
sever
viral
hemorrhag
fever
syndrom
caus
ebola
viru
ebov
transmit
direct
contact
bodi
fluid
infect
person
object
contamin
viru
infect
anim
world
health
organ
declar
evd
epidem
public
health
emerg
intern
concern
sever
global
econom
burden
fatal
ebov
infect
stage
patient
usual
die
antibodi
respons
current
rapid
blood
test
diagnos
ebov
infect
includ
antigen
antibodi
captur
use
elisa
rna
detect
use
rtqpcr
within
day
onset
symptom
moreov
nanotechnologybas
colorimetr
paperbas
immunoassay
method
recent
report
detect
ebola
viru
unfortun
method
limit
laboratori
stateofth
art
soa
diagnost
time
confirm
ebola
infect
vari
h
day
caus
delay
therapeut
approach
thu
develop
costeffect
rapid
sensit
select
sensor
detect
evd
pointofcar
poc
certainli
worth
explor
establish
rapid
diagnost
decid
therapeut
review
highlight
soa
ebola
diagnost
also
call
develop
rapid
select
sensit
poc
detect
ebov
global
health
care
propos
adopt
miniatur
electrochem
ebov
immunosens
detect
viru
level
pm
concentr
within
min
compar
day
elisa
test
nm
level
ebolavirus
ebov
belong
famili
filovirida
taxonom
group
envelop
nonseg
neg
singlestrand
rna
virus
includ
genera
marburgviru
cuevaviru
ebolaviru
beech
et
al
peter
peter
van
kinh
nguyen
et
al
fig
speci
identifi
ebov
zair
bundibugyo
sudan
reston
tai
forest
speci
capabl
caus
diseas
differ
extent
progress
virul
fatal
rate
vari
bundibugyo
sudan
zair
feldmann
tan
et
al
bundibugyo
zair
sudan
speci
associ
outbreak
africa
zair
speci
ebov
lead
west
african
outbreak
baiz
et
al
fauci
ebola
viru
diseas
evd
first
appear
simultan
outbreak
yang
et
al
one
nzara
sudan
yambuku
democrat
republ
congo
breman
johnson
maganga
et
al
latter
occur
villag
near
ebola
river
henc
name
diseas
evd
zoonosi
caus
high
mortal
epidem
human
popul
burd
feldmann
geisbert
mitman
swami
et
al
recent
outbreak
west
africa
march
biggest
bizarr
sinc
first
outbreak
huge
number
mortal
morbid
case
chan
chertow
et
al
drazen
et
al
countri
ruthless
attack
guinea
sierra
leon
liberia
may
partli
due
handicap
health
facil
infrastructur
resourc
lack
knowledg
dietari
habit
funer
rite
insuffici
suppli
dispos
equip
hospit
ebola
epidem
declar
public
health
emerg
intern
concern
health
agenc
august
carodart
cowl
yu
evd
fact
sheet
per
recent
report
cdc
june
total
case
suspect
probabl
confirm
laboratoryconfirm
case
death
sourc
http
ca
consider
effort
made
health
agenc
commun
awar
develop
test
method
explor
marker
evd
analysi
carodart
kanapathipillai
et
al
macintyr
et
al
rivera
messaoudi
rosenbaum
b
ebov
appear
singl
filament
particl
fig
ssrna
genet
materi
along
seven
transcript
unit
code
seven
structur
protein
tabl
addit
two
secret
solubl
protein
sgp
ssgp
may
act
decoy
disrupt
host
immun
system
absorb
antigp
antibodi
choi
croyl
feldmann
feldmann
geisbert
mohan
et
al
nyakatura
et
al
rivera
messaoudi
rougeron
et
al
takada
fruit
bat
belong
pteropodida
famili
thought
natur
ebov
host
ebov
introduc
human
popul
close
contact
blood
secret
organ
bodili
fluid
infect
anim
chimpanze
gorilla
fruit
bat
monkey
forest
antelop
porcupin
ebov
choi
croyl
feldmann
nyakatura
et
al
rivera
messaoudi
rougeron
et
al
takada
transmit
humantohuman
via
direct
contact
broken
skin
mucou
membran
blood
secret
organ
bodili
fluid
infect
peopl
indirectli
via
contamin
fomit
healthcar
worker
frequent
infect
treat
patient
suspect
confirm
evd
carodart
feldmann
et
al
martin
et
al
tan
et
al
ebov
undergo
enzoot
epizoot
life
cycl
fig
infect
host
cell
attach
receptor
via
gp
glycoprotein
get
endocytos
host
vesicl
ctype
lectin
dcsign
dcsignr
play
crucial
role
bind
ebola
glycoprotein
augment
infect
ebola
enter
earli
endosom
via
macropinocytosi
cultur
cell
like
dendrit
cell
gp
glycoprotein
modul
due
action
cathepsin
l
cat
l
cathepsin
b
cat
b
upon
interact
host
fusion
viru
vesicl
membran
happen
ribonucleocapsid
releas
follow
transcript
replic
start
nucleoprotein
encapsid
newli
synthet
genom
interact
ribonucleotid
matrix
protein
virion
releas
via
bud
plasma
membran
escrt
complex
hatfil
et
al
kawaoka
miller
et
al
sullivan
et
al
sullivan
et
al
clinic
phase
ebola
broadli
categor
phase
incub
prodrom
convalesc
deterior
phase
ebola
incub
period
clinic
ebola
infect
initi
day
symptom
like
fever
malais
fatigu
bodi
ach
sore
joint
gastrointestin
issu
like
epigastr
pain
nausea
vomit
diarrhea
associ
issu
conjunctiv
infect
chest
pain
arthralgia
myalgia
hiccup
late
complic
z
day
compris
gastrointestin
hemorrhag
secondari
infect
meningoenceph
persist
neurocognit
abnorm
shock
hypotens
fig
bah
et
al
baiz
et
al
burd
karwowska
lyon
et
al
rosenbaum
rougeron
et
al
saijo
et
al
advanc
diagnost
detect
ebov
outcom
studi
relat
fundament
appli
research
field
ebola
confirm
evd
control
fig
signific
effort
made
agenc
like
un
sagripanti
lytl
interpret
refer
color
figur
legend
reader
refer
web
version
articl
mission
ebola
emerg
respons
cdc
nih
awar
prevent
ebola
transmiss
possibl
diagnost
accomplish
safeti
train
network
mass
level
conduct
local
intern
agenc
butler
cowl
yu
goodman
lamontagn
et
al
macintyr
et
al
soa
need
rapid
diagnost
diagnost
tool
util
ebola
viru
summar
tabl
fig
fig
respect
base
social
assess
impact
bottomup
approach
ie
introduct
new
tool
smart
assay
rapid
detect
develop
effici
diagnost
tool
increas
health
qualiti
ebola
infect
patient
import
farrar
piot
fauci
hill
et
al
kanapathipillai
mani
intern
health
agenc
nih
public
health
agenc
canada
democrat
republ
congo
provid
medic
financi
support
ebola
infect
remot
area
howev
portabl
diagnost
tool
unavail
power
devic
oper
refriger
store
biosampl
still
challeng
howev
elisa
immunoassay
genet
modifi
gene
protein
monoclon
antibodi
viralantigen
base
ebov
detect
approach
success
execut
need
facil
perform
ebola
detect
diagnost
use
method
limit
applic
techniqu
field
saijo
et
al
updat
laboratori
diagnosi
ebola
marburg
hemorrhag
fever
summar
grolla
et
al
research
describ
laboratori
diagnosi
ebov
avail
nation
intern
laboratori
delay
diagnost
due
time
consum
sampl
collect
limit
storag
complic
transport
sensit
sampl
rais
demand
setup
qualiti
diagnosi
laboratori
local
level
dhillon
et
al
describ
bottomup
integr
approach
scaledup
strategi
could
use
monitor
ebov
dhillon
et
al
iwen
et
al
describ
integr
approach
base
autom
laboratori
instrument
along
recommend
compani
regulatori
agenc
ebola
manag
safe
control
clinic
laboratori
iwen
et
al
studi
base
ebov
infect
patient
conduct
critic
part
manag
propos
martin
et
al
avail
diagnost
tast
capabl
rule
patient
experienc
symptom
h
author
suggest
need
method
detect
ebola
onset
symptom
also
warrant
neg
ebola
test
within
h
martin
et
al
util
diagnost
protocol
safeti
process
ebola
infect
patient
usa
describ
et
al
doctor
suggest
safe
manag
menu
base
procedur
monitor
infect
relat
progress
longer
cours
evd
treatment
outcom
studi
use
healthcar
profession
manag
cure
similar
infecti
diseas
hill
et
al
research
group
highlight
major
issu
demand
develop
rapid
select
sensit
miniatur
ebola
sens
system
reduc
form
factor
recognit
screen
detect
ebov
level
portabl
sens
platform
could
provid
manag
ebola
outbreak
monitor
ebov
increas
detect
limit
sure
improv
health
qualiti
techniqu
util
till
date
detect
ebola
viru
diseasesinfectionsprogress
discuss
prehaud
et
al
purpos
nucleoprotein
np
glycoprotein
gp
gabon
strain
base
method
detect
ebov
infect
human
prehaud
et
al
author
propos
clone
sequenc
np
gp
gene
gabones
strain
isol
ebola
found
circul
viru
zair
subtyp
ebola
strain
gp
np
synthes
cell
express
recombin
protein
develop
elisa
detect
igg
antibodi
convalesc
human
sera
gabon
zair
measur
made
use
ng
antigen
well
elisa
plate
np
gp
base
elisa
method
detect
igg
igm
antibodi
success
could
use
earli
diagnosi
howev
assay
show
issu
fals
result
thu
kawaoka
upon
bind
cellsurfac
receptor
ebola
get
intern
endosom
within
endosom
endosom
proteas
cathepsin
b
cathepsin
l
slash
viral
protein
ntermin
fragment
cathepsin
b
digest
aid
fusion
viral
envelop
endosom
membran
releas
viral
genom
cytoplasm
upon
releas
proteolysi
prevent
inhibitor
therefor
infect
advanc
develop
select
method
detect
ebov
clinic
level
demand
prehaud
et
al
sandwich
elisa
system
base
ebov
antigendetect
use
monoclon
antibodi
mab
prepar
via
immun
np
zair
subtyp
develop
develop
system
detect
ng
recombin
np
util
mab
also
found
react
correspond
region
np
deriv
reston
sudan
subtyp
research
claim
system
use
laboratori
detect
ebola
viru
low
level
formenti
et
al
propos
elisa
rtpcr
base
detect
ebola
viru
oral
fluid
ebolaoutbreak
hemorrhag
fever
evhf
republ
congo
formenti
et
al
use
serum
oral
fluid
specimen
ebola
kaushik
et
al
biosensor
bioelectron
viru
infect
patient
along
normal
patient
confirm
evhf
studi
author
fail
detect
igg
ebola
oral
fluid
sampl
patient
whose
serum
sampl
seroposit
besid
patient
posit
serum
rtpcr
result
also
found
posit
oral
fluid
specimen
formenti
et
al
elisa
assay
develop
nakayama
et
al
detect
filoviru
speciesspecif
antibodi
histag
secret
form
transmembran
gp
five
differ
ebov
speci
use
antigen
detect
filoviru
speci
specif
antibodi
assay
perform
antisera
collect
mice
immun
viruslik
particl
human
nonhuman
primat
infect
viru
littl
crossreact
igg
antibodi
observ
mous
antisera
result
suggest
viru
specif
igm
antibodi
specif
detect
acut
infect
patient
develop
method
could
use
ebola
diagnost
manag
nakayama
et
al
lucht
et
al
propos
need
mab
develop
ebola
diagnost
elisa
kit
analyz
zair
strainebov
lucht
et
al
author
produc
specif
mab
mice
immun
inactiv
viral
particl
direct
viral
structur
protein
effici
develop
mab
test
use
elisabas
antigen
captur
protocol
assay
exhibit
detect
viru
infect
sampl
moreov
sd
inactiv
materi
also
detect
use
antigen
captur
elisa
method
lucht
et
al
later
research
group
develop
immunofiltr
base
assay
detect
rapid
diagnost
ebov
infect
fig
lucht
et
al
antigen
captur
base
approach
detect
ebola
viru
chemic
inactiv
clinic
sampl
develop
assay
test
use
known
viru
stock
assay
acknowledg
firstgener
onsit
tool
detect
ebola
viru
within
min
author
propos
develop
assay
use
ebov
progress
among
anim
human
lucht
et
al
select
np
found
express
ebola
viru
cytomegaloviru
immedi
earli
stage
promot
conduct
relat
experi
select
cell
line
infect
baculoviru
express
ebov
np
perform
base
antigen
detect
ebola
viru
igg
method
sensit
ebola
detect
altern
highli
complic
procedur
perform
facil
ikegami
et
al
also
promot
assay
detect
reston
subtyp
ebov
subtyp
use
hela
cell
line
express
relat
ebov
np
fig
ikegami
et
al
author
perform
detect
select
viru
specif
igg
hyperimmun
rabbit
sera
monkey
result
show
develop
assay
sensit
reston
subtyp
zair
subtyp
ebola
viru
sampl
author
believ
develop
method
potenti
seroepidemiolog
studi
viru
infect
anim
ikegami
et
al
recent
martin
et
al
publish
review
highlight
ebov
pathogenesi
human
use
histopatholog
martin
et
al
result
show
viru
infect
affect
liver
significantli
histopatholog
success
differenti
normal
cell
viru
ebola
viru
hemorrhag
filoviru
fever
effect
cell
organ
group
also
summar
pathogenesi
affect
mononuclear
phagocyt
system
activ
proinflammatori
cytokin
releas
immun
impair
dysregul
endotheli
viru
progress
viral
replic
outcom
signific
understand
viral
pathogenesi
epidem
transmiss
histopatholog
analysi
host
organ
howev
pathogenesi
viru
infect
mani
unansw
issu
futur
research
direct
explor
pathway
mechan
better
diagnosi
first
time
sanchez
et
al
demonstr
rtpcr
detect
character
ebov
infect
sampl
collect
human
nonhuman
premis
sanchez
et
al
author
employ
rtpcr
method
detect
viral
rna
infect
bodi
fluid
tissu
well
known
infect
littl
chang
take
place
nucleotid
amino
acid
sequenc
gp
ebola
viru
subtyp
comparison
uninfect
origin
repres
nonstructur
secret
gp
sgp
success
detect
acut
infect
human
sanchez
et
al
drosten
et
al
mention
diseas
clinic
difficult
detect
diagnos
screen
novel
primer
detect
probe
design
specif
relat
viru
use
dna
databas
entri
assay
sensit
measur
optim
valid
use
vitrotranscrib
rna
detect
limit
estim
use
probit
regress
analysi
averag
measur
time
within
hr
receiv
sampl
patient
develop
pcr
method
suggest
import
part
diagnost
procedur
detect
virusspecif
igg
igm
drosten
et
al
trombley
et
al
design
assay
detect
quantif
multipl
hemorrhag
fever
virus
trombley
et
al
set
viru
specif
assay
analyz
design
assay
measur
marburg
viru
exhibit
detect
rang
plaqueform
unit
pfu
pcr
result
present
report
suggest
viral
rna
realtim
qrtpcr
assay
adopt
diagnost
tool
identif
analysi
evd
trombley
et
al
rapid
detect
ebov
marburg
viru
via
target
np
gene
zair
strain
use
rttaqmanpcr
assay
tool
report
huang
et
al
correspond
threshold
standard
rna
transcript
rttaqmanpcr
report
work
detect
viru
copi
wide
rang
among
rna
copiesml
viru
cultur
supernat
equival
rna
molecul
per
infect
outcom
present
report
also
clearli
indic
presenc
mani
noninfecti
particl
author
suggest
qrtpcr
one
amongst
main
analyt
tool
util
sensit
select
rapid
ebov
huang
et
al
multiplex
approach
detect
pathogen
use
dna
dnabas
fluoresc
nanobarcod
methodolog
describ
li
et
al
author
synthes
dendrimerlik
dl
dna
base
fluoresc
intens
code
nanobarcod
contain
inbuilt
code
probe
molecular
recognit
nanobarcod
util
multiplex
detect
sever
pathogen
dna
use
fluoresc
microscopi
dot
blot
flow
cytometri
author
use
unknown
dna
sampl
isol
three
pathogen
speci
name
anthraci
ebola
sar
coronaviru
analysi
present
method
exhibit
detect
limit
mole
attomol
within
dna
multipl
pathogen
detect
simultan
use
nanobarcod
methodolog
author
claim
dldna
use
structur
scaffold
function
probe
multiplex
molecular
sens
reli
detect
precis
fluoresc
color
ratio
use
detect
deadli
virus
li
et
al
bar
et
al
rais
issu
direct
role
ebola
virusgp
membran
fusion
need
lowph
activ
clear
bar
et
al
author
develop
assay
base
galactosidas
lacz
report
gene
target
cell
detect
cytoplasm
exchang
indic
membran
fusion
ebov
infect
cell
zair
speci
fig
outcom
studi
demonstr
direct
role
ebov
progress
inhibit
antigp
igg
bar
et
al
et
al
develop
onestep
revers
transcriptionloop
mediat
isotherm
amplif
rtlamp
assay
detect
zair
ebov
via
target
trailer
region
viral
genom
kurosaki
et
al
report
assay
detect
copi
artifici
zair
ebov
rna
within
min
real
timemonitor
detect
also
perform
detect
ffu
propag
viru
rtlamp
assay
found
select
zair
ebov
good
side
method
need
sophist
instrument
seem
suitabl
ebov
diagnosi
clinic
infield
kurosaki
et
al
yu
et
al
report
polyclon
pab
mab
ebola
virusgp
use
detect
ebola
viru
studi
relat
divers
author
develop
surfac
plasma
reson
spr
quartz
crystal
microbal
qcm
immunosensorbas
pab
mab
detect
ebola
viru
produc
differ
strain
besid
mab
also
abl
recogn
differenti
ebov
gp
among
human
nonhuman
primat
immunosensor
strategi
found
select
yu
et
al
recent
paper
base
synthet
gene
network
investig
parde
et
al
detect
ebov
fig
parde
et
al
author
explor
invitro
paperbas
platform
capabl
detect
viru
smartli
use
engin
gene
circuit
visual
transduct
smallmolecul
rna
actuat
genet
switch
rapid
prototyp
complex
gene
circuit
programm
vitro
diagnost
includ
glucos
sensor
strainspecif
ebov
sensor
success
demonstr
use
approach
test
method
rapid
costeffect
sensit
perform
detect
diagnost
base
antibodi
sequenc
detail
sensor
prepar
methodolog
illustr
fig
cd
parde
et
al
yanik
et
al
develop
fig
label
free
biosensor
base
optofluid
nanoplasmon
detect
live
virus
vsv
ptebola
vaccinia
biolog
specimen
clinic
relev
concentr
yanik
et
al
sensor
due
high
signal
throughput
without
complic
mechan
optic
isol
propos
effici
tool
detect
small
high
viru
level
direct
detect
vsv
ptebola
vaccinia
also
ad
advantag
low
detect
rang
pfuml
detect
rang
pfuml
along
dynam
magnitud
order
success
demonstr
moreov
sensor
develop
multiplex
manner
wherein
variou
viral
antibodi
immobil
select
detect
pathogen
desir
bodi
fluid
author
claim
extraordinari
light
transmiss
phenomena
detect
broad
rang
pathogen
use
immedi
clinic
yanik
et
al
daaboulet
al
purpos
specif
sensit
virusnanoparticl
nm
imag
sens
assay
ie
singl
particl
interferometr
reflect
imag
sensor
spiri
daaboul
et
al
nanoparticlesantibodi
microarray
base
assay
possess
high
throughput
rapid
size
variat
interact
target
viru
detect
viru
particl
replicationcompet
wildtyp
vesicular
stomat
viru
vsv
defect
vsv
ebola
marburg
vsv
demonstr
use
spiri
fig
sens
interact
nanoparticlesantibodi
viru
chang
size
particl
differenti
modifi
viru
accord
genom
length
low
detect
limit
pfuml
blood
within
hr
respect
ebola
marburg
vsv
pseudotyp
achiev
author
claim
detect
virus
express
hemorrhag
fever
viru
gp
use
spiri
signific
pointofne
devic
detect
infecti
viru
diagnost
daaboul
et
al
current
rapid
blood
test
use
diagnos
ebov
infect
includ
antigen
antibodi
captur
elisa
rna
detect
rtpcr
within
day
onset
symptom
howev
elisa
test
procedur
cumbersom
health
care
worker
base
high
infect
natur
viru
includ
sever
wash
elisa
plate
period
time
elisa
difficult
perform
poc
facil
rtpcr
complic
genet
divers
due
rapidli
chang
natur
genom
sequenc
viru
method
limit
laboratori
thu
turnaround
time
confirm
laboratori
ebola
diagnost
result
day
caus
delay
therapeut
approach
need
effect
ebola
test
kit
smart
diagnost
tool
poc
ebov
sens
identifi
diseas
rapid
infect
monitor
easi
oper
prevent
epidem
highlight
vogel
brief
avail
corgenix
senova
testingbas
bloodantibodi
analysi
demonstr
ebov
detect
human
patient
howev
longer
detect
time
travel
biosampl
still
obstacl
howev
test
method
base
sophist
devic
demand
need
high
expert
perform
test
expert
explain
good
bad
side
devic
also
due
rapid
onsit
detect
recommend
method
screen
tool
poc
remot
area
expert
believ
optim
senova
could
potenti
produc
thousand
sens
unit
per
day
assaycost
would
recent
usaid
gate
foundat
fund
variou
program
promot
research
develop
new
diagnost
method
improv
stateoftheart
ebola
diagnost
expert
suggest
increas
pcr
base
lab
manag
ebola
diagnost
larg
volum
popul
vogel
conclus
develop
costeffect
rapid
sensit
select
sensor
detect
ebov
poc
need
diagnos
ebola
file
clinic
believ
achiev
use
electrochem
immunesens
methodolog
electrochem
sensor
proven
potenti
sensit
select
detect
marker
pm
level
recent
sensor
integr
zair
strain
sensor
sudan
strain
sensor
microfluid
system
sampl
autom
miniatur
devic
poc
target
analyt
detect
cruz
et
al
kaushik
et
al
kaushik
et
al
vasudev
et
al
howev
methodolog
yet
explor
evd
colleg
medicin
colleg
engin
fiu
propos
develop
poc
system
consist
electrochem
ebola
imunosensor
fabric
use
specif
monoclon
antibodi
detect
ebola
viru
low
pm
level
within
min
compar
day
elisa
test
nm
level
develop
devic
use
rapid
screen
ebola
strain
use
avail
specif
antiebola
viru
antibodi
base
immunosens
also
estim
ebola
viru
level
enabl
faster
therapeut
approach
tremend
effort
made
scientist
develop
appropri
vaccin
ebov
infect
fig
scientist
public
health
organ
regulatori
bodi
pharmaindustri
attend
urgent
meet
name
ebola
vaccinean
intern
prioriti
organ
geneva
aim
meet
discuss
soa
possibl
futur
prospect
develop
vaccin
treat
evd
potenti
two
vaccin
util
ebola
ie
approv
glaxo
smithlin
nation
institut
allergi
infecti
diseas
virusgp
approv
new
link
genet
public
health
agenc
canada
discuss
kanapathipillai
et
al
report
except
two
drug
vaccin
preliminari
stage
monoval
form
vaccinebas
zair
strain
found
effect
ebola
west
africa
fig
vaccin
demonstr
safeti
immunogenec
enough
product
vaccin
still
exist
challeng
public
health
relat
agenc
request
pharma
compani
increas
vaccin
product
safeti
advanc
immedi
therapi
case
futur
ebola
epidem
recent
li
et
al
de
clercq
describ
advanc
develop
therapeuticsvaccin
prevent
control
ebov
infect
author
suggest
ebov
posit
patient
isol
immedi
confirm
medic
expert
volunt
inhabit
must
immun
prophylact
vaccin
avoid
possibl
infect
break
transmiss
chain
group
report
multipl
drug
evd
develop
avail
potenti
antivir
zmapp
favipiravir
antiebola
zmapp
target
viral
entri
favipiravir
target
rna
replic
step
complet
erad
ebov
develop
power
drug
vaccin
urgent
requir
de
clercq
li
et
al
carett
et
al
explor
featur
ebov
entri
pathway
use
filovirus
investig
potenti
antivir
strategi
author
describ
filoviru
gp
base
viral
membran
fusion
escap
vesicular
compart
carett
et
al
requir
protein
cholesterol
transport
global
gene
associ
human
cell
util
explor
compon
relat
unusu
entri
pathway
fig
author
explor
aspect
lysosom
function
found
associ
identifi
gene
indic
filovirus
exploit
organel
differ
author
purpos
investig
role
hereditari
diseas
gene
viral
entri
infect
pathogenesi
use
develop
therapi
cure
filoviru
carett
et
al
bornholdt
et
al
fig
explor
structur
rearrang
ebov
beget
multipl
function
viral
life
cycl
bornholdt
et
al
well
known
protein
perform
multipl
distinct
role
ebov
life
cycl
author
use
multipl
crystal
structur
explain
biochemistri
cellular
microscopi
relat
rearrang
respect
distinct
function
ebov
life
cycl
variat
structureshift
properti
provid
ad
informat
develop
antivir
drug
therapeut
moreov
provid
way
establish
correl
ebov
genom
essenti
function
target
protein
bornholdt
et
al
among
four
major
main
strain
ebov
respons
hemorrhag
fever
zair
subtyp
relat
ebola
outbreak
exhibit
highest
lethal
uncontrol
due
rapid
viru
progress
allow
develop
immun
lack
effect
antivir
therapi
et
al
develop
vaccin
cure
ebola
viru
infect
author
demonstr
immun
boost
dnacombin
adenovir
vector
encod
viral
protein
gener
cellular
humor
immun
cynomolgu
macaqu
author
observ
tcell
mediat
humor
immun
base
system
exhibit
therapeut
signific
clear
viru
moreov
antibodi
titer
cellular
prolif
respons
also
exhibit
improv
immun
protect
sullivan
et
al
sullivan
et
al
sullivan
et
al
research
also
explor
ebov
infect
pathway
progress
need
receptor
role
gp
genet
variabl
infect
transmiss
outcom
studi
provid
pathway
develop
vaccin
evd
therapeut
chandran
et
al
explor
catb
catl
reduc
multipl
ebov
zair
subtyp
use
select
proteas
inhibitor
proteasedefici
cell
line
chandran
et
al
detail
antivir
studi
inhibitor
necessari
develop
therapeut
ebov
genom
surveil
elucid
ebov
origin
transmiss
ebola
gire
et
al
via
sequenc
ebola
viru
genom
isol
patient
fig
gire
et
al
interhost
intrahost
genet
variat
accumul
character
viral
pattern
epidem
ebola
exhibit
genet
variabl
chang
distinct
lineag
studi
catalog
mutat
includ
fix
non
synonym
chang
posit
high
risk
ebov
infect
use
conduct
relat
studi
author
releas
genom
surveil
promot
ebola
research
global
identifi
viral
determin
transmiss
dynam
monitor
viral
chang
adapt
investig
genom
surveil
help
develop
therapi
diagnost
tool
health
care
gire
et
al
uebelho
et
al
explor
first
time
marv
ebov
revers
genet
systembas
secret
gaussia
luciferas
gluc
establish
two
screen
method
develop
antivir
therapeut
fig
uebelho
et
al
first
method
base
minigenom
replicon
facil
exhibit
screen
viru
replic
inhibitor
use
gluc
level
anoth
method
base
gluc
util
report
gene
product
encod
recombin
infect
thu
variat
gluc
level
correl
viral
growth
quantif
antivir
effect
research
character
system
proof
concept
propos
minigenom
infecti
viru
platform
use
bioinformat
need
develop
antiviru
therapi
fig
illustr
microarray
configur
detect
mechan
detect
ebola
viru
use
singl
particl
interferometr
reflect
imag
sensor
spiri
specif
antibodi
immobil
onto
microarray
detect
viru
via
colorimetr
base
imag
illustr
green
red
blue
spot
repres
antivsv
antiebov
antimarv
probe
respect
interpret
refer
color
figur
legend
reader
refer
web
version
articl
uebelho
et
al
immunogen
antibodi
neutral
activ
antigen
determin
domain
zair
strain
ebov
fragment
mfl
contain
furin
site
intern
loop
explor
develop
singl
rvsvbase
polyval
vaccin
fig
outcom
suggest
recombin
protein
plasmid
mfl
fragment
zair
ebov
gp
show
high
level
neutral
antibodi
induc
cellular
immun
respons
mice
also
observ
intern
fusion
loop
furin
site
contain
domain
show
signific
contribut
immunogen
mfl
investig
vaccin
found
effect
use
antigen
produc
neutral
antibodi
cure
ebov
choi
et
al
first
time
investig
singl
dose
respiratori
recombin
adenovirusbas
vaccin
longterm
protect
lethal
ebola
infect
nonhuman
primat
choi
et
al
dose
respiratori
sublingu
infecti
viru
particl
ivp
kg
adcagoptzgp
strongli
induc
respons
cell
specif
ebov
gp
antibodi
vaccin
investig
three
primat
show
improv
immun
respons
ebola
rodent
significantli
formul
vaccin
exhibit
protect
challeng
week
immun
howev
case
sublingu
develop
antibodi
unabl
neutral
make
vaccin
unprotect
choi
et
al
role
humor
versu
cellular
immun
recombin
vesicular
stomat
viru
rvsv
vaccin
protect
zair
strain
ebov
investig
use
model
ebov
infect
anim
marzi
et
al
develop
rvsvzair
ebola
gp
vaccin
test
group
cynomolgu
macaqu
deplet
b
cell
detail
analysi
result
suggest
role
antibodi
crucial
rvsvbase
vaccin
therapeut
ebov
infect
marzi
et
al
mohan
et
al
explor
phenomena
antigen
subvers
novel
ebov
escap
strategi
via
improv
host
immun
mohan
et
al
author
report
dna
immun
andor
truncat
glycoprotein
isoform
sgp
among
sgp
abil
compet
antibodi
sgp
secret
ebov
infect
quantiti
correl
viru
progress
author
correl
outcom
ebov
vaccinolog
claim
import
elicit
immun
rapid
clear
ebov
infect
antigen
subvers
antigen
subvers
repres
novel
viru
escap
strategi
like
help
ebov
evad
host
immun
may
repres
import
obstacl
ebov
vaccin
design
mohan
et
al
demonstr
human
adenoviru
type
vector
capabl
encod
ebola
viru
gp
gener
protect
immun
acut
zair
ebola
viru
infect
stanley
et
al
therapeut
unabl
protect
anim
stanley
et
al
show
first
time
chimpanze
deriv
replic
defect
adenoviru
vaccin
modifi
mva
gener
longer
protect
ebov
infect
anim
stanley
et
al
macrophag
dendrit
cell
antigen
present
cell
apc
exhibit
earli
invivo
sustain
target
ebov
infect
recent
effect
pyridinyl
imidazol
inhibitor
mapk
ebov
infect
human
apc
viru
mediat
cytokin
product
demonstr
jackson
et
al
use
ebov
like
particl
vlp
result
suggest
util
mapk
inhibitor
block
ebov
infect
replic
thu
may
propos
potenti
therapeut
discuss
highlight
effort
made
research
direct
explor
ebov
infect
pathway
hostcel
target
possibl
antibodiesantigen
genom
sequenc
develop
vaccin
evd
howev
potenti
vaccin
avail
yet
market
could
use
ebov
infect
thu
current
review
also
call
increas
signific
effort
advanc
develop
effect
vaccin
cure
evd
deliber
ebola
expert
dr
aileen
marti
depart
medicin
fiu
claim
lack
appropri
safeti
work
station
effici
select
rapid
ebola
diagnost
methodolog
main
challeng
fight
ebov
futur
effect
evd
monitor
treatment
demand
establish
level
laboratori
intern
explor
fundament
appli
research
ebov
develop
effect
diagnost
system
enough
tool
prevent
ebov
transmiss
pathogenesi
replic
health
effect
explor
rnaprotein
elisa
immunofluoresc
assay
rtqpcr
dispos
immunoassay
spr
qcm
base
ebola
detect
serv
good
clinic
level
recognit
detect
ebov
unfortun
random
fals
result
exhibit
method
still
unsolv
issu
howev
smart
miniatur
poc
ebola
sens
devic
diagnost
kit
explor
yet
select
rapid
detect
ebov
level
need
time
therapeut
thu
develop
costeffect
rapid
sensit
select
sensor
detect
ebov
poc
worth
explor
possibl
achiev
use
electrochem
immunosens
methodolog
nanoelectron
nanoplatform
base
electrochem
immunosensor
base
miniatur
devic
capabl
detect
target
analyt
pm
level
clinic
diseas
locat
integr
miniatur
sens
devic
nemsmem
also
increas
autom
sampl
accur
precis
measur
hypothes
develop
specif
ebola
monoclon
antibodi
base
electrochem
immunosensor
detect
ebov
select
pm
level
within
min
devic
use
rapid
screen
estim
ebov
level
especi
earli
stage
investig
miniatur
potentiostat
rapid
sensit
select
detect
ebov
poc
help
decid
therapeut
decis
ebola
infect
patient
moreov
rapid
assess
ebov
use
miniatur
electrochem
ebola
sens
system
improv
ebov
progress
person
health
care
patient
fig
futur
fulli
optim
poc
ebola
sens
devic
use
onsit
diagnost
infect
patient
would
great
import
decid
therapeut
review
highlight
ebov
associ
health
effect
pathogenesi
ebola
soa
ebola
diagnost
health
care
decid
therapeut
impact
research
conduct
explor
strategi
control
transmiss
epidem
effort
also
made
improv
detect
perform
ebola
diagnost
tool
particular
achiev
rapid
select
detect
decid
therapi
challeng
discrimin
among
symptom
ebola
deadli
fever
like
malaria
diarrhea
remain
unresolv
rais
demand
develop
highli
sensit
diagnost
tool
earli
stage
avail
diagnost
tool
capabl
detect
ebola
viru
concentr
longer
analysi
time
portabl
limit
applic
field
accord
soa
miniatur
sens
technolog
poc
ebola
detect
achiev
via
adopt
electrochem
ebola
immunosens
methodolog
review
request
initi
high
level
multidisciplinari
research
collabor
biologist
nanotechnologist
engin
develop
smart
compart
integr
poc
ebola
sens
devic
environ
success
demonstr
ebola
sens
devic
infield
ebola
viru
detect
pm
level
within
minut
viru
strain
diseas
site
decid
therapeut
aim
futur
research
approach
